Abstract:Drug toxicity prediction is an important step in ensuring patient safety during drug design studies. While traditional preclinical studies have historically relied on animal models to evaluate toxicity, recent advances in deep-learning approaches have shown great promise in advancing drug safety science and reducing animal use in preclinical studies. However, deep-learning-based approaches also face challenges in handling large biological data sets, model interpretability, and regulatory acceptance. In this review, we provide an overview of recent developments in deep-learning-based approaches for predicting drug toxicity, highlighting their potential advantages over traditional methods and the need to address their limitations. Deep-learning models have demonstrated excellent performance in predicting toxicity outcomes from various data sources such as chemical structures, genomic data, and high-throughput screening assays. The potential of deep learning for automated feature engineering is also discussed. This review emphasizes the need to address ethical concerns related to the use of deep learning in drug toxicity studies, including the reduction of animal use and ensuring regulatory acceptance. Furthermore, emerging applications of deep learning in drug toxicity prediction, such as predicting drug-drug interactions and toxicity in rare subpopulations, are highlighted. The integration of deep-learning-based approaches with traditional methods is discussed as a way to develop more reliable and efficient predictive models for drug safety assessment, paving the way for safer and more effective drug discovery and development. Overall, this review highlights the critical role of deep learning in predictive toxicology and drug safety evaluation, emphasizing the need for continued research and development in this rapidly evolving field. By addressing the limitations of traditional methods, leveraging the potential of deep learning for automated feature engineering, and addressing ethical concerns, deep-learning-based approaches have the potential to revolutionize drug toxicity prediction and improve patient safety in drug discovery and development.

Recent Advances in Omics, Computational Models, and Advanced Screening Methods for Drug Safety and Efficacy

Research progress in drug toxicology based on systems biology

Review of Current and “omics” Methods for Assessing the Toxicity (genotoxicity, Teratogenicity and Nephrotoxicity) of Herbal Medicines and Mushrooms

Integration of metabolomics and transcriptomics in nanotoxicity studies

Transforming Toxicity Assessment through Microphysiology, Bioprinting, and Computational Modeling

Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction

Predictive Systems Toxicology

Quantitative knowledge-based analysis in compound safety assessment

Genomic and Proteomic Approaches for Predicting Toxicity and Adverse Drug Reactions.

Quantitative Proteomics for Drug Toxicity.

Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology

A Review on the Recent Applications of Deep Learning in Predictive Drug Toxicological Studies.

Preface to the special issue of Food and Chemical Toxicology on "New approach methodologies and machine learning in food safety and chemical risk assessment: Development of reproducible, open-source, and user-friendly tools for exposure, toxicokinetic, and toxicity assessments in the 21st century"

In Silico Prediction Of Adverse Drug Reactions And Toxicities Based On Structural, Biological And Clinical Data

Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends

In silico ADME-Tox modeling: progress and prospects

Digitalization of toxicology: improving preclinical to clinical translation

Machine learning and artificial intelligence in toxicological sciences.

In Silico Prediction Of Chemical Toxicity For Drug Design Using Machine Learning Methods And Structural Alerts

Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals